Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:07:03.216Z.
Calculation as of: 2026-10-06T17:07:03.216Z.
Quote observation: 2026-10-06T17:04:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cd3ead22764b77a02cf3e742533c366d0c9255af04c84535b20f2b2666bee2a
PEG RATIO
N/A
Gain Therapeutics, Inc.
Market Cap
$71.66M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $71.66M | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $70.30M | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $69.19M | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $69.31M | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $67.93M | N/A |
| iBio, Inc. (IBIO)vs › | $67.52M | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $76.14M | N/A |
| Outset Medical, Inc. (OM)vs › | $75.54M | N/A |
| Hyperfine, Inc. (HYPR)vs › | $77.39M | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $77.15M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
